Peripheral Arterial Disease Market Size and Growth Fueled by Innovative Therapies

The Peripheral Arterial Disease (PAD) industry is witnessing significant evolution with the advent of innovative treatment methods and heightened awareness regarding vascular health. This growth trajectory is underpinned by emerging clinical research and evolving patient management approaches, aligning with broader healthcare advancements in cardiovascular disease.

Market size and Overview

The peripheral arterial disease market is estimated to be valued at USD 5.14 Bn in 2025 and is expected to reach USD 8.25 Bn by 2032, growing at a compound annual growth rate (CAGR) of 7.00% from 2025 to 2032.

Key Takeaways

- Dominating Region: North America leads the Peripheral Arterial Disease Market share in 2025, supported by advanced healthcare infrastructure and increased adoption of novel therapies.
- Fastest Growing Region: Asia Pacific displays the highest cadence of market growth, fueled by improving healthcare access and government initiatives targeting cardiovascular diseases.

- Segment: Treatment Type
- Dominant Sub-segment: Endovascular Therapy, with recent introduction of drug-coated balloons gaining traction in 2024.
- Fastest Growing Sub-segment: Pharmacological Therapy, highlighted by increased use of antiplatelet drugs as seen in clinical trials conducted throughout 2025.

- Segment: Diagnostic Approach
- Dominant Sub-segment: Ankle-Brachial Index (ABI) testing, widely used for quick PAD diagnosis globally.
- Fastest Growing Sub-segment: Imaging Techniques such as duplex ultrasonography, which saw adoption rises influenced by more accurate diagnostic capabilities reported in 2024.

- Segment: End User
- Dominant Sub-segment: Hospitals, due to large-scale surgical interventions and inpatient treatments.
- Fastest Growing Sub-segment: Ambulatory Surgical Centers, as minimally invasive procedures increase in volume and accessibility.

Market Key Trends

A key market trend shaping the Peripheral Arterial Disease market in 2025 is the accelerated adoption of drug-coated balloon (DCB) technologies in endovascular interventions. For instance, several clinical studies published in 2024 have shown significant improvement in patient outcomes using DCBs over traditional angioplasty, reducing restenosis rates by up to 30%. This advancement is catalyzing market growth by expanding treatment options and driving up market revenue across key geographies, notably in North America and Europe.

Additionally, regulatory approvals around expedited access pathways for these devices have opened new market opportunities, particularly in APAC countries, where healthcare infrastructure is rapidly advancing. The enhanced efficacy of DCBs coupled with increasing physician preference is expected to continue influencing market dynamics profoundly.

Key Players

Key companies driving the Peripheral Arterial Disease market include:

- Novartis
- Bayer
- Pfizer
- Amgen
- Sanofi
- Other significant market players also include specialist medical device firms and pharmaceutical manufacturers.

In 2024 and 2025, several market companies have focused on growth strategies such as strategic partnerships for research and development in minimally invasive treatments. For example, collaborations between pharmaceutical and device companies have resulted in innovative combination therapies that improve symptom management. Furthermore, expansions into emerging markets and investments in clinical trials have enhanced product portfolios and market penetration, thereby bolstering industry size and business growth for these market players.

FAQs

1. Who are the dominant players in the Peripheral Arterial Disease market?
The market is led by several global pharmaceutical and medical device companies noted for their innovation and strategic growth initiatives. Companies like Novartis, Bayer, and Pfizer are among the top contributors shaping industry trends.

2. What will be the size of the Peripheral Arterial Disease market in the coming years?
The PAD market size is projected to increase from USD 5.14 billion in 2025 to USD 8.25 billion by 2032, driven by sustained market growth due to advancements in diagnosis and treatment.

3. Which end-user segment holds the largest growth opportunity?
While hospitals remain dominant due to complex interventions, ambulatory surgical centers are the fastest growing segment, owing to the rise of outpatient minimally invasive procedures.

4. How will market development trends evolve over the next five years?
Market trends indicate further adoption of innovative endovascular therapies, with drug-coated balloons playing a key role. Advancements in diagnostic imaging are also expected to refine disease management and expand market scope.

5. What is the nature of the competitive landscape and challenges in the Peripheral Arterial Disease market?
Competition is intense among pharmaceutical and device market players striving for new market opportunities. Challenges include regulatory approvals, reimbursement policies, and the need for continuous clinical validation of emerging therapies.

6. What go-to-market strategies are commonly adopted in the Peripheral Arterial Disease market?
Leading companies emphasize strategic partnerships, diversification of product offerings, and geographical expansion while investing in clinical research to support market growth strategies and enhance market share.


This comprehensive Peripheral Arterial Disease market report builds on detailed market research and insights, ensuring that stakeholders can make well-informed decisions based on accurate market size, trends, and revenue data.

‣ Get this Report in Japanese Language: 末梢動脈疾患市場

‣ Get this Report in Korean Language: 말초동맥질환시장  

‣ Read More Related Articles:  Fitness Tracker Market

Author Bio:

Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163 )